




aln collaboration with bluebird bio, Inc. bluebirdbio bln collaboration with Acceleron Pharma, Inc. ACCELERON

In collaboration with Agios Pharmaceuticals, Inc. 29ios dln collaboration with GEMoaB Monoclonals GmbH.

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, VIDAZA®, and IDHIFA® are registered trademarks of Celgene Corporation.







	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
SOLID TUMORS					
ABRAXANE® (paclitaxel protein- bound particles for injectable suspension) (albumin-bound) (US)/ (paclitaxel formulated as albumin- bound nanoparticles) (EU)	Breast: Metastatic				
	Non-small cell lung: Advanced (First-line)				
	Pancreatic: Metastatic (First-line)				
	Pancreatic: Adjuvant				
	Gastric: Metastatic (Japan) ^a				
Marizomib	Glioblastoma				
Tislelizumab (BGB-A317)b	Non-small cell lung cancer				
CC-90011					
CC-90010 (BET inhibitor)					
CC-95251					
INFLAMMATION & IMMU	NOLOGY				
OTEZLA® (apremilast)	Psoriatic arthritis				
	Psoriasis (Mild to Moderate)				
	Psoriasis (Moderate to Severe)				
	Psoriasis (Pediatric)				
	Behçet's disease				
	Scalp psoriasis				
	Genital psoriasis				
Ozanimod	Relapsing multiple sclerosis				
	Ulcerative colitis				
	Crohn's disease				
CC-93538	Eosinophilic esophagitis				
Iberdomide (CC-220)	Systemic lupus erythematosus				
CC-90001	Idiopathic pulmonary fibrosis				
CC-90006	Psoriasis				



^aTrial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. ^bIn collaboration with BeiGene, Ltd. ^{BeiGene} ABRAXANE[®] and OTEZLA[®] are registered trademarks of Celgene Corporation.